Prevalence and types of drug-resistant variants in Chinese patients with acute hepatitis B

Journal of Medical Virology

Volumn 87, Issue 9, 2015, Pages 1527-1531

  Su, Feifei ^a   Dai, Jianyi ^a   Yang, Shoufeng ^a   Jiang, Xiangao ^a   Cui, Xiaoya ^a   Ning, Hongye ^a   Li, Junhua ^a   Huang, Mohe ^a  

^a WENZHOU CENTRAL HOSPITAL   (China)

Author keywords

Acute hepatitis B; Drug resistant; Hepatitis B virus; Nucleos(t)ide analogues

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; BILIRUBIN; ENTECAVIR; LAMIVUDINE; TELBIVUDINE; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; GUANINE; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE; THYMIDINE;

ACUTE HEPATITIS B; ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CHINA; CLONAL SEQUENCING; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; INVESTIGATIVE PROCEDURES; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; ANALOGS AND DERIVATIVES; CLASSIFICATION; DRUG EFFECTS; EPIDEMIOLOGY; GENETIC VARIATION; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; MIDDLE AGED; MISSENSE MUTATION; TIME FACTOR; VIROLOGY; YOUNG ADULT;

HEPATITIS B VIRUS;

ADENINE; ADULT; ANTIVIRAL AGENTS; CHINA; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENETIC VARIATION; GUANINE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION, MISSENSE; ORGANOPHOSPHONATES; PREVALENCE; RNA-DIRECTED DNA POLYMERASE; THYMIDINE; TIME FACTORS; YOUNG ADULT;

EID: 84937072813     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.24006     Document Type: Article

References (26)

1. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27:1670-1677.
2. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A, Locarnini S. 2003. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125:292-297.
3. Baxa DM, Thekdi AD, Golembieski A, Krishnan PV, Sharif O, Kizy A, Shetron-Rama L, Jovanovich J, Chappell BJ, Snow-Lampart A, Borroto-Esoda K, Gordon SC. 2013. Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States. J Hepatol 58:212-216.
4. Chinese Society of Infectious Diseases PCSoH. 2000. Management scheme of diagnostic and therapy criteria of viral hepatitis. Zhonghua Gan Zang Bing Za Zhi 8:6.
5. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ. 2006. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44:1656-1665.
6. Coppola N, Tonziello G, Colombatto P, Pisaturo M, Messina V, Moriconi F, Alessio L, Sagnelli C, Cavallone D, Brunetto M, Sagnelli E. 2013. Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B. J Infect 67:322-328.
7. Delaney WE, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, Miller MD, Xiong S. 2003. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 77:11833-11841.
8. Devi U, Locarnini S. 2013. Hepatitis B antivirals and resistance. Curr Opin Virol 3:495-500.
9. Ghany MG, Doo EC. 2009. Antiviral resistance and hepatitis B therapy. Hepatology 49:S174-S184.
10. Hayashi K, Katano Y, Takeda Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Nakano I, Yano M, Goto H, Yoshioka K, Toyoda H, Kumada T. 2007. Comparison of hepatitis B virus subgenotypes in patients with acute and chronic hepatitis B and absence of lamivudine-resistant strains in acute hepatitis B in Japan. J Med Virol 79:366-373.
11. Jindal A, Kumar M, Sarin SK. 2013. Management of acute hepatitis B and reactivation of hepatitis B. Liver Int 33:164-175.
12. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, Han S, Poynard T, Myers M, Chao G, Lloyd D, Brown NA. 2005. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129:528-536.
13. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV. 2009. 2-Year GLOBE trial results: Telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 136:486-495.
14. Liu Y, Wang C, Zhong Y, Li X, Dai J, Ren X, Xu Z, Li L, Yao Z, Ji D, Wang L, Zhang L, Wong VW, Zoulim F, Xu D. 2011. Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection. J Viral Hepat 18:e29-e39.
15. Luo Q, Zhong Y, Yang Y, Xiong Q, Hu Z, Lu W, Huang P, Zhang N. 2012. Clinical characteristics and chronicity of acute hepatitis B induced by lamivudine-resistant strains. J Med Virol 84:1558-1561.
16. Osiowy C, Villeneuve JP, Heathcote EJ, Giles E, Borlang J. 2006. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J Clin Microbiol 44:1994-1997.
17. Papatheodoridis G, Buti M, Cornberg M, Janssen H, Mutimer D, Pol S, Raimondo G, Dusheiko G, Lok A, Marcellin P. 2012. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57:167-185.
18. Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, Locarnini S, Martin P, Richman DD, Zoulim F. 2008. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: Recommendations for a standardized approach. Gastroenterology 134:405-415.
19. Qi X, Xiong S, Yang H, Miller M, Delaney WE. 2007. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 12:355-362.
20. Schildgen O, Sirma H, Funk A, Olotu C, Wend UC, Hartmann H, Helm M, Rockstroh JK, Willems WR, Will H, Gerlich WH. 2006. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 354:1807-1812.
21. Singla B, Chakraborti A, Sharma BK, Kapil S, Chawla YK, Arora SK, Das A, Dhiman RK, Duseja A. 2013. Hepatitis B virus reverse transcriptase mutations in treatment Naive chronic hepatitis B patients. J Med Virol 85:1155-1162.
22. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P, Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner N, Locarnini S, Colonno RJ. 2004. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 48:3498-3507.
23. Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, Fang J, Yu CF, Zhang S, Mazzucco CE, Eggers B, Hsu M, Plym MJ, Poundstone P, Yang J, Colonno RJ. 2007. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 51:902-911.
24. Warner N, Locarnini S, Kuiper M, Bartholomeusz A, Ayres A, Yuen L, Shaw T. 2007. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother 51:2285-2292.
25. Xu Z, Liu Y, Xu T, Chen L, Si L, Wang Y, Ren X, Zhong Y, Zhao J, Xu D. 2010. Acute hepatitis B infection associated with drug-resistant hepatitis B virus. J Clin Virol 48:270-274.
26. Zoulim F, Locarnini S. 2009. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137:1593-1608, e1591-e1592.